ArticleInternational journal of nanomedicine2022
Combined Prussian Blue Nanozyme Carriers Improve Photodynamic Therapy and Effective Interruption of Tumor Metastasis.
Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Development of a Hypoxia-Triggered Supramolecular Nanoplatform for Synergistic Hypoxia Alleviation and Amplified Photodynamic Cancer Therapy.Molecules (Basel, Switzerland) · 2026Article
- Light-Controlled Modulation of the Endocannabinoid System: Photoswitchable Ligands for Cannabinoid and TRPV1 Receptors.International journal of molecular sciences · 2026Review
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- Molecularly engineered BODIPY photosensitizers for combined cancer phototherapy and immunotherapy.Frontiers in pharmacology · 2026Review
- Recent advances in photodynamic therapy systems based on pillar[n]arene host-guest chemistry.Frontiers in chemistry · 2026Review
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.Materials today. Bio · 2025Review
- Nanodynamic therapy for cancer: mechanistic innovations, targeting strategies and multimodal treatments.Journal of translational medicine · 2025Review
- Metal hexacyanoferrates in photodynamic and photothermal therapies.Biophysical reviews · 2025Review
- Emerging engineered nanozymes: current status and future perspectives in cancer treatments.Nanoscale advances · 2025Review
- Wash-free fluorescent tools based on organic molecules: Design principles and biomedical applications.Exploration (Beijing, China) · 2025Review
- Evolution of nMOFs in photodynamic therapy: from porphyrins to chlorins and bacteriochlorins for better efficacy.Frontiers in pharmacology · 2025Review
- Targeted photodynamic therapy: enhancing efficacy through specific organelle engagement.Frontiers in pharmacology · 2025Review
- Photo-Thermally Controllable Tumor Metabolic Modulation to Assist T Cell Activation for Boosting Immunotherapy.International journal of nanomedicine · 2024Article
- Porphyrin-engineered nanoscale metal-organic frameworks: enhancing photodynamic therapy and ferroptosis in oncology.Frontiers in pharmacology · 2024Review
- Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology.Advanced healthcare materials · 2023Review
- Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The multifunctional Prussian blue/graphitic carbon nitride nanocomposites for fluorescence imaging-guided photothermal and photodynamic combination therapy.RSC advances · 2022Article
- Progress and prospects of nanozymes for enhanced antitumor therapy.Frontiers in chemistry · 2022Review
- Progress and perspectives of platinum nanozyme in cancer therapy.Frontiers in chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Photodynamic therapy (PDT) as a new technique for theranostics is to kill tumor cells by activating photosensitizer and interacting with oxygen (O Methods: Prussian blue (PBs) was firstly synthesized by hydrothermal method, which was then etched by hydrochloric acid to obtained hollow Prussian blue nanoparticles (HPBs). Afterwards, Au-Pt nanozymes were in situ growing on the HPBs by reduction method to prepare Au-Pt@HPBs (APHPBs). Owing to the hollow structure of APHPBs, photosensitizer Ce6 can be easily and efficiently loaded into it to obtain Ce6-Au-Pt@HPBs (Ce6-APHPBs). After ce6-APHPBS regulation, photoacoustic imaging and hypoxic fluorescence imaging were then used to evaluate changes in hypoxic TME in vivo. Finally, under the assistant of Ce6-APHPBs, we evaluated the inhibitory effect of enhanced PDT on primary and metastatic tumors. Results: We first designed and synthesized Ce6 loaded hollow prussian blue nanoparticles with Au-Pt nanozymes grown in situ on it. Both in vitro and in vivo experiments show that the prepared Ce6-APHPBs have good biosafety and could effectively degrade the overexpressed H Conclusion: Ce6-APHPBs designed by us could not only efficiently enhance PDT but also regulate TME to reduce tumor metastasis and prolong survival of mice, which provide a novel idea and strategy for clinical PDT and metastatic tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.